Company
Melbourne, VIC
Every investor coverage indicates participated in a round St Vincent's Hospital Melbourne raised.
Companies St Vincent's Hospital Melbourne acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Kieran McCaffrey | Gynaecologist (former) | Forbes Australia |
Stories naming St Vincent's Hospital Melbourne. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Medical device firm Epiminder has joined the ASX, its shares dipping below issue price on debut, with the $125 million IPO proceeds earmarked for an American launch of its implantable epilepsy monitoring system next year.
Also Startup Daily
Forbes Australia profile of Grace Toombs, founder of women's health startup June Health, recalling her Startmate accelerator acceptance and her plans for an endometriosis clinic.
AFR reports the titanium artificial heart maker is chasing $100 million for trials after a Sydney patient spent three months on the device; OneVentures is named as a backer.
Weekly roundup covering five Australian startups' raises: an insurtech Series E, a digital ID Series A, medtech and proptech funding, and a recycling platform's equity crowdfunding campaign.
Breakthrough Victoria is putting $5 million into Neo-Bionica, a Melbourne medical device manufacturer, to grow its prototyping, clinical trial and production capabilities, with the company expecting as many as 45 additional roles.
Also Breakthrough Victoria·SmartCompany·Startup Daily·@AuManufacturing·SmartCompany·Startup Daily·@AuManufacturing
Biotech firm BiomeBank raised $10.65 million from Ellerston Capital, the South Australian Venture Capital Fund and The Hospital Research Foundation to expand manufacturing and advance its microbiome therapies.
Also SmartCompany·Techboard
Fibrotech Therapeutics raised $3 million in Series A backing from Brandon Capital-managed funds MRCF, BBF1 IIF and Uniseed to advance fibrosis drug FT011 through Phase Ib trials.